ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rashes"

  • Abstract Number: 2037 • 2019 ACR/ARP Annual Meeting

    Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity

    Theresa Lu 1, Noa Schwartz 2, Thomas Li 2, William Shipman 3, Dragos Dasoveanu 3, Yong Liu 4, Niroshana Anandasabapathy 4, Henry Lee 4, Ali Jabbari 5, James Krueger 5, Bebak Mehrara 6, Keila Veiga2, Kira Minkis 4 and David Oliver 2, 1Hospital for Special Surgery, Weill Cornell Medicine (Microbiology and Immunology), New York, 2Hospital for Special Surgery, New York, 3Hospital for Special Surgery; Weill Cornell Medicine, New York, 4Weill Cornell Medicine (Dermatology), New York, 5Rockefeller University, New York, 6Memorial Sloan Kettering Cancer Center, New York

    Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus.  Lesions can be disfiguring and have a negative impact on patients’ quality…
  • Abstract Number: 2584 • 2017 ACR/ARHP Annual Meeting

    Apremilast in Patients with Lupus Rashes

    Robert S. Katz, Rush University Medical Center, Chicago, IL

    Background/Purpose: Apremilast has been approved by the FDA for treatment of psoriasis and psoriatic arthritis. Because side effects are few, we decided to use it…
  • Abstract Number: 1368 • 2016 ACR/ARHP Annual Meeting

    Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease

    Edward J. Oberle1,2, Dominic O. Co3,4, Yvonne Chiu3,4, Michelle Bayer4,5, Adam Huber6, Hatice Ezgi Baris7 and Susan Kim8, 1Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, 2Pediatrics, Ohio State University, Columbus, OH, 3Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 4Children's Hospital of Wisconsin, Milwaukee, WI, 5Dermatology, Medical College of Wisconsin, Milwaukee, WI, 6Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, 7Boston Children's Hospital, Boston, MA, 8Division of Immunology, Boston Children's Hospital, Boston, MA

    Background/Purpose:  Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of the skin and striated muscle. A subset of patients can present with rash only, labeled…
  • Abstract Number: 1775 • 2016 ACR/ARHP Annual Meeting

    Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus

    Shawn Kwatra1, Michelle Petri2 and Wei Fu3, 1Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    ACR Abstract Authors: Shawn G. Kwatra1, Wei Fu2, Michelle Petri2 1Department of Dermatology, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD Title:…
  • Abstract Number: 305 • 2015 ACR/ARHP Annual Meeting

    The “Sleeve Sign”� in Dermatomyositis

    Arash Lahoutiharahdashti1, Julie J. Paik2, Jemima Albayda1, Andrew Mammen3,4 and Lisa Christopher-Stine5, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, 4NIAMS, NIH, Bethesda, MD, 5Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathies, characterized by proximal skeletal muscle weakness and skin manifestations. Several skin eruptions have been described…
  • Abstract Number: 1202 • 2013 ACR/ARHP Annual Meeting

    Two Family Kindreds With Blau’s Syndrome Associated With Unusual NOD2 Mutations

    Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

    Background/Purpose: The aim of this study was to report families of Blau’s syndrome with unusual NOD2 gene variants. Methods: Two proband patients were seen, and their clinical…
  • Abstract Number: 1201 • 2013 ACR/ARHP Annual Meeting

    A Progress Report On An Emerging Disease: NOD2-Associated Autoinflammatory Disease

    Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

    Background/Purpose: We recently reported a new disease designated as NOD2-associated autoinflammatory disease (NAID). The aim of this study was to update the progress on defining the disease. Methods: A…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology